Balaxi Pharmaceuticals Ltd Financials
Company Logo

Balaxi Pharmaceuticals Ltd Financial Statement

Balaxi Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue22.45
Operating Expense19.68
Net Profit1.66
Net Profit Margin7.39
Earning Per Share0.30
EBIDTA2.79
Effective Tax Rate20.22
Invest in Balaxi Pharmaceuticals Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Balaxi Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual70.20
Operating Expenses Annual64.96
Operating Profit Annual7.63
Interest Annual1.54
Depreciation0.51
Net Profit Annual3.65
Tax Annual1.93

Balaxi Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning17.87
Cash Flow from Operations-1.83
Cash Flow from Investing0.47
Cash Flow from Financing27.55
Cash Flow at the End44.06

Balaxi Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)11.04
PBIT Margin (%)10.31
PBT Margin (%)4.10
Net PROFIT Margin (%)5.20
Return On Networth / Equity (%)3.42
Return On Networth /Employed (%)5.99
Return On Assets (%)3.02
Total Debt / Equity (X)0.13
Asset Turnover Ratio (%)0.58

Balaxi Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual7.10
Total Current Assets Annual122.90
Non Current Assets Annual31.46
Total Shareholders Funds Annual121.55
Total Assets Annual154.36

Balaxi Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

0.83

Reported

0.84

Surprise

1.20%

Jun 2024

EPS beaten by 1.20%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 3.79%

Get Your FAQs Right

As of Nov 22, 2024, Balaxi Pharmaceuticals Ltd has a market capitalization of 2,702.37 Cr. Value Research classifies it as a Mid-Cap company.
Yes, Balaxi Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.13.
In FY 2023 , Balaxi Pharmaceuticals Ltd recorded a total revenue of approximately 70.20 Cr marking a significant milestone in the company's financial performance.
Balaxi Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and -0.2% annually, respectively..
Balaxi Pharmaceuticals Ltd's current PE ratio is 740.38.
Balaxi Pharmaceuticals Ltd's ROCE averaged 20.0% from the FY ending March 2022 to 2024, with a median of 21.9%. It peaked at 33.0% in March 2022, reflecting strong capital efficiency over the period..
Balaxi Pharmaceuticals Ltd's latest EBIT is Rs. 7.12 Cr, surpassing the average EBIT of Rs. 16.60 Cr over the 5 years..